Welcome to our dedicated page for Jasper Therapeutics SEC filings (Ticker: JSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jasper Therapeutics, Inc. (JSPR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed clinical-stage biotechnology issuer. Jasper files reports and current updates with the U.S. Securities and Exchange Commission in connection with its development of briquilimab, an aglycosylated monoclonal antibody targeting KIT (CD117) for chronic mast cell diseases such as chronic urticaria and asthma.
Current Reports on Form 8-K featured here include items on quarterly financial results and corporate updates, public offerings of common stock, pre-funded warrants and common warrants, and material corporate actions such as workforce reductions and operating plan changes. These filings describe how Jasper intends to use offering proceeds to advance preclinical and clinical development of briquilimab in mast cell driven diseases and to fund general corporate purposes.
Filings also disclose Nasdaq listing details for Jasper’s voting common stock (trading symbol JSPR) and redeemable warrants (trading symbol JSPRW), as well as information on shareholder meetings, director elections, advisory votes on executive compensation and the appointment of the independent registered public accounting firm. Selected 8-Ks incorporate press releases that summarize clinical data from the BEACON study in chronic spontaneous urticaria, the ETESIAN study in allergic asthma and related open-label extension work, along with safety and efficacy observations.
On Stock Titan, these SEC documents are paired with AI-powered tools that help readers quickly identify key sections, such as financing terms, use of proceeds, study-related disclosures and governance decisions. Users can review Jasper’s historical and recent filings to understand the company’s reporting history, capital structure developments and the regulatory context for its briquilimab clinical programs.
Jasper Therapeutics reported its fourth quarter and full-year 2025 results and provided a corporate update focused on briquilimab, its antibody therapy for mast cell–driven diseases such as chronic urticaria and asthma. For 2025, operating expenses were $83.9 million, driven by $63.1 million in research and development and $20.8 million in general and administrative costs. Net loss for 2025 was $75.8 million compared with $71.3 million in 2024, reflecting continued investment in clinical programs. As of December 31, 2025, Jasper held $28.7 million in cash and cash equivalents, down from $71.6 million a year earlier, and reported total assets of $35.8 million and stockholders’ equity of $4.2 million. The company plans to begin enrolling patients in the Phase 2b portion of a planned Phase 2b/3 chronic spontaneous urticaria study in the second half of 2026, pending capital availability.
Jasper Therapeutics, Inc. files its annual report outlining progress on briquilimab, a monoclonal antibody targeting mast cell driven diseases such as chronic spontaneous urticaria, chronic inducible urticaria and asthma. The company highlights positive early-stage clinical data, a shift of resources away from stem cell transplant uses, and a strategy to build a focused mast cell therapeutics franchise.
Jasper holds worldwide rights to briquilimab under exclusive licenses from Amgen and Stanford, supported by patent families expected to expire in 2027 with newer applications potentially extending protection into the 2040s. The report also details regulatory pathways, manufacturing via Lonza, competitive landscape, and substantial ongoing funding needs with a history of operating losses and going-concern risk.
Jasper Therapeutics, Inc. reported Schedule 13G filings showing shared voting and dispositive power by several Millennium-related entities and an affiliate. Integrated Core Strategies (US) LLC reports shared voting and dispositive power over 1,624,076 shares (5.8%).
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report shared voting and dispositive power over 1,629,013 shares (5.8% each). The filings include a Joint Filing Agreement dated 02/24/2026.
Jasper Therapeutics received an Amendment No. 4 to a Schedule 13D from a group of Carlyle- and Abingworth-affiliated entities updating their ownership in its voting common stock. The group reports beneficial ownership of 1,088,310 shares of common stock, representing 3.8% of the class, based on 27,984,039 shares outstanding as of November 6, 2025. The filing notes that, as of this amendment, the reporting persons have ceased to be beneficial owners of more than five percent of Jasper’s outstanding common stock and that they have not effected any transactions in the stock during the past 60 days. Voting and dispositive power over these shares is shared among the affiliated investment entities.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report beneficial ownership of 1,764,848 shares of Jasper Therapeutics voting common stock, representing 6.3% of the class. They have shared voting and shared dispositive power over all of these shares, with no sole authority.
The firms state that the securities were acquired and are held in the ordinary course of business and not to change or influence control of Jasper Therapeutics. A joint filing agreement confirms that both entities are reporting together, with signatures provided by an attorney-in-fact dated January 6, 2026.
Morgan Stanley filed a Schedule 13G reporting a significant ownership position in Jasper Therapeutics, Inc. voting common stock. Morgan Stanley reports beneficial ownership of 1,969,785 shares, representing 7.0% of the class, with shared voting and shared dispositive power over these shares.
Affiliated entity Morgan Stanley Capital Services LLC reports beneficial ownership of 1,903,420 shares, or 6.8% of the class, also with shared voting and dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Jasper Therapeutics.
Jasper Therapeutics CEO and President Jeetinder Singh Mahal received a stock option covering 500,000 shares of voting common stock on February 6, 2026. The option has an exercise price of $1.35 per share and expires on February 6, 2036.
According to the vesting terms, one quarter of the option vests on February 6, 2027, with the remaining three quarters vesting in equal monthly installments over the following 36 months, conditioned on continued service with the company.
A shareholder group associated with Anders Hove filed an amended Schedule 13G reporting beneficial ownership of 1,486,492 shares of Jasper Therapeutics, Inc. common stock, equal to 5.3% of the class. This ownership is held through investment entities including Acorn Bioventures, L.P. and Acorn Bioventures 2, L.P., with related general partners Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC. The percentages are based on 27,984,039 shares of common stock outstanding as of November 6, 2025. The reporting persons certify the shares were not acquired and are not held for the purpose of changing or influencing control of Jasper Therapeutics.
Jasper Therapeutics, Inc. reported that it has released a press release with positive updated clinical data from its BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with chronic spontaneous urticaria, along with data from an open-label extension study in chronic spontaneous and chronic inducible urticaria. The company is also hosting a conference call and webinar at 8:00 a.m. Eastern Time on January 8, 2026 to present these updated BEACON and open-label extension results. The press release and the related investor presentation are provided as exhibits to this report.
Jasper Therapeutics reported leadership changes, with the Board determining that, effective January 5, 2026, Ron Martell would cease serving as Chief Executive Officer and President. Under his amended employment agreement, this termination is treated as without cause, and he is eligible for 18 months of base salary and up to 18 months of COBRA premium payments, subject to signing a release in favor of the company.
Effective the same date, the Board appointed current Chief Operating Officer Jeet Mahal as Chief Executive Officer and President and as a Class III director, making him the company’s principal executive officer. His annualized salary was increased to $600,000, and he is eligible for an annual performance bonus of up to 50% of base salary, with future compensation adjustments at the Compensation Committee’s discretion. The Board also named current Chairperson Thomas G. Wiggans as Executive Chair, further formalizing his leadership role.